Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Dexamethasone 27Melphalan 22Cyclophosphamide 15Peripheral Blood Stem Cell Transplantation 14Filgrastim 13Bortezomib 12Calcium Dobesilate 9Lenalidomide 7fludarabine phosphate 6Whole-Body Irradiation 5Mycophenolic Acid 5Cyclosporine 5Thalidomide 4Interferon-alpha 4Etoposide 4Busulfan 4miridesap 3dexamethasone acetate 3Radiotherapy 3Epoetin Alfa 3Doxycycline 3Darbepoetin alfa 3Carboplatin 3pomalidomide 2liposomal amphotericin B 2ixazomib 2daratumumab 2birtamimab 2Thiotepa 2Tacrolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Immunoglobulin Light-chain Amyloidosis × 4'-deoxy-4'-iododoxorubicin × Clear all
NCT00003853 2012-11-12

4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis

National Cancer Institute (NCI)

Phase 2 Completed
45 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡